Annelies Janssens
University of Antwerp · 140 works · 1,939 citations · h-index 22
Top works
- Perioperative Nivolumab in Resectable Lung Cancer
- Performance of Fully Covered Self-Expanding Metallic Stents in Benign Airway Strictures
- Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review
- Endobronchial Lipomas: Rare Benign Lung Tumors, Two Case Reports
- Imaging of urgencies and emergencies in the lung cancer patient
- An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients
- Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study
- SARS-CoV-2 and cancer: Are they really partners in crime?
- Recent developments in the treatment of small cell lung cancer
- Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody
- Pseudo-acute kidney injury secondary to tepotinib
- Small Airway Disease in Pre-Chronic Obstructive Pulmonary Disease with Emphysema: A Cross-Sectional Study
- Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
- Successful bilateral lung transplant from a donor with a tracheal right upper lobe bronchus
- Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
- Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
- Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study
- Coping Strategy Influences Quality of Life in Patients With Advanced Lung Cancer by Mediating Mood
- Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
- Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial